Email updates

Keep up to date with the latest news and content from BMC Pharmacology and BioMed Central.

Open Access Research article

In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate

Jaume Carrió and Montserrat Portús*

Author Affiliations

Laboratory of Parasitology. Departament de Microbiologia i Parasitologia Sanitàries, Facultat de Farmàcia, Universitat de Barcelona, 08028 Barcelona, Spain

For all author emails, please log on.

BMC Pharmacology 2002, 2:11  doi:10.1186/1471-2210-2-11

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2210/2/11


Received:21 January 2002
Accepted:2 May 2002
Published:2 May 2002

© 2002 Carrió and Portús; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background

Leishmaniasis is a common parasitic disease in Southern Europe, caused by Leishmania infantum. The failures of current treatment with pentavalent antimonials are partially attributable to the emergence of antimony-resistant Leishmania strains. This study analyses the in vitro susceptibility to pentavalent antimony of intracellular amastigotes from a range of L. infantum strains, derived from the same infected animal, during in vitro and in vivo passages and after host treatment with meglumine antimoniate.

Results

SbV-IC50 values for strains from two distinct isolates from the same host and one stock after two years of culture in NNN medium and posterior passage to hamster were similar (5.0 ± 0.2; 4.9 ± 0.2 and 4.4 ± 0.1 mgSbV/L, respectively). In contrast, a significant difference (P < 0.01, t test) was observed between the mean SbV-IC50 values in the stocks obtained before and after treatment of hosts with meglumine antimoniate (4.7 ± 0.4 mgSbV/L vs. 7.7 ± 1.5 mgSbV/L). Drug-resistance after drug pressure in experimentally infected dogs increased over repeated drug administration (6.4 ± 0.5 mgSbV/L after first treatment vs. 8.6 ± 1.4 mgSbV/L after the second) (P < 0.01, t test).

Conclusions

These results confirm previous observations on strains from Leishmania/HIV co-infected patients and indicate the effect of the increasing use of antimony derivatives for treatment of canine leishmaniasis in endemic areas on the emergence of Leishmania antimony-resistant strains.

Background

Leishmaniasis, a protozoan parasitic disease, is endemic in 88 countries, with an estimated yearly incidence of 1–1.5 million cases of cutaneous leishmaniasis and 500,000 cases of visceral leishmaniasis. Three hundred and fifty million people are estimated to be at risk, and there is an overall prevalence of 12 million cases [1]. Zoonotic visceral leishmaniasis occurs mainly in Latin America, the Mediterranean Basin and Asia. The parasite responsible for this disease is Leishmania infantum and the dog is the main reservoir. Leishmaniasis has re-emerged in recent years because of the increase in risk factors, some of which are related to HIV infection and intravenous drug use. In Western Europe the cumulative number of cases of Leishmania/HIV co-infections, reported to the WHO up to December 1999 was 1627 [2]. Canine leishmaniasis in endemic areas is a serious veterinary and public health problem. The dog is one of the main hosts responsible for the spread of visceral leishmaniasis, which was initially only in rural areas, but is now extending to suburbs. Significant foci are located on the periphery of cities where small gardens encourage the presence of sandfly vectors [2]. The main treatment for dogs is through pentavalent antimonials. Nevertheless these drugs usually produces only temporary remission of clinical signs, and relapses are frequent [3]. Other alternatives such as amphotericin B [4], aminosidine [5] and allopurinol [6] have also shown variable results. The ineffectiveness of treatment for cutaneous and visceral leishmaniasis is attributable to host physiology, the compound and its preparation and the susceptibility of the parasite strain to the drugs [7-11].

Grogl et al. [12] induced promastigote resistance to Pentostam in vitro in Leishmania strains from American cutaneous leishmaniasis, by discontinuous exposure of promastigotes to the drug. These authors observed that after repeated in vitro passages and in vivo infection, resistance was stable in the absence of drug pressure. The decrease in SbV susceptibility in vitro of intracellular amastigotes of Leishmania strains obtained during a second episode of anthroponotic [10] or zoonotic human visceral leishmaniasis [9,13] has also been observed. In addition, Gramiccia et al [3] observed that the in vivo activity of SbV in mice infected with L. infantum strains from dogs treated with meglumine antimoniate was lower than in mice infected with strains obtained before the dogs were treated.

Here we evaluated the in vitro susceptibility to SbV of intracellular amastigotes of L. infantum strains, derived from one infected animal. These strains were obtained in a number of studies that involved repeated in vitro cultivation, hamster and canine experimental infections and two courses of treatment with meglumine antimoniate. This study aims to determine the stability of in vitro SbV susceptibility of L. infantum stocks during successive in vitro and in vivo passages and the role of host treatment in this susceptibility.

Results

The in vitro susceptibility to SbV of two L. infantum strains (MCAN/ES/92/BCN-82 and MCAN/ES/92/BCN-83), simultaneously isolated from bone marrow and lymph node aspirate from the same dog were almost identical (IC50: 5.0 ± 0.2 and 4.9 ± 0.2 mgSbV/L). Also, the SbV-IC50 for MCRI/ES/94/BCN-328 (4.4 ± 0.1 mg/L) was very similar to that of the original strain (BCN-83) (Figure 1), despite repeated in vitro passages and hamster inoculation.

thumbnailFigure 1. Flow chart for the origin of L. infantum stocks, derived from the same infected dog, after several in vitro and in vivo passages.

The mean IC50 in these strains from untreated hosts (BCN-82, BCN-83 and BCN-328) (4.7 ± 0.4 mgSbV/L) was lower (P < 0.01, t test) than in five strains (BCN-335, BCN-336, BCN-323, BCN-329 and BCN-331) isolated after dogs had been treated with meglumine antimoniate (7.7 ± 1.5 mgSbV/L). The IC50 was also lower in strains obtained after one treatment course with meglumine antimoniate (BCN-335 and BCN-336) (6.4 ± 0.5 mgSbV/L) than in strains obtained after a second course with this drug (BCN-323, BCN-329 and BCN-331) (8.6 ± 1.4 mgSbV/L) (Table 1).

Table 1. Growth rate of promastigotes and SbV susceptibility of intracellular amastigotes, of L. infantum strains, after repeated in vitro and in vivo passages and dogs treatment with meglumine antimoniate.

The promastigote growing capacity of strains BCN-82, BCN-83 and BCN-328 was higher than in strains from dogs treated with meglumine antimoniate (Table 1).

Discussion and Conclusions

Leishmania isolates from an infected host have a multiclonal composition with an heterogeneous expression of different phenotypes such as drug resistance [12], virulence [14] or growth capacity in vitro. The variations in clonal composition difficult comparison and interpretation of results from studies performed with different strains and, even, with the same strain after repeated passagesin vitro or in vivo. Differences in the expression of certain phenotypes, such as "virulence" or "growth rate in vitro" may modify the clonal composition of the strain during successive passages. This, in turn, may modify the expression of other phenotypes like drug resistance.

In our study no differences were observed in SbV susceptibility of intracellular amastigotes of L. infantum strains isolated from untreated animals, despite repeated in vitro passages and hamster infection. In contrast, SbV susceptibility was lower in strains isolated after treatment with meglumine antimoniate of experimentally infected dogs. It is worth emphasising that the Priorat, where the strain was first isolated, is a rural region, with a high prevalence of canine leishmaniasis [15] and where dogs were rarely treated at the time when the first isolation was performed. We can thus assume that the drug pressure received by strains BCN 82 and BCN-83 was very low.

The in vitro growth capacity of Leishmania varies from one isolate to another and isolates that are initially difficult to grow adapt to the culture after repeated passages, probably because of the selection of phenotypes with higher growing rate. The promastigote growth rate in NNN and Schenider's culture media of all strains isolated after treatment was lower than in the original strain (BCN-83), without modification in the course of successive passages. This suggests that the selected clones more resistant to SbV also had a different promastigote growth rate phenotype

Our results correlates with previous studies performed with other designs, methodologies and Leishmania species [3,9,10,12,13]. The study reinforces that the SbV susceptibility of Leishmania strains is stable over in vitro and in vivo passages, in the absence of drug pressure. Moreover, SbV susceptibility decreases after host treatment with meglumine antimoniate. We conclude that the increasing use of antimony derivatives in veterinary practice in Southern Europe will lead to a rapid overspread of L. infantum SbV-resistant strains.

Material and Methods

Parasites and drug

L. infantum strains BCN-82 and BCN-83 were isolated from bone marrow and lymph node aspirate from an asymptomatic dog, from the Priorat region (Spain), a highly endemic area for canine leishmaniasis [15]. BCN-83 was maintained for almost two years by repeated passages in NNN medium, it was then inoculated by intraperitoneal injection into one hamster. After three months the parasite was isolated again from the hamster spleen in NNN medium (coded as BCN-328) and promastigotes were used to experimentally infect dogs [16] for subsequent pharmacokinetic studies [17,18].

Dogs were treated with meglumine antimoniate (Glucantime, Rhône Mérieux) (20.4 mg of Sb/kg/12 h), for two 10-day periods, each separated by an interval of 10 days [17].

After a temporary remission of the symptoms, all dogs relapsed and two isolates were obtained from dogs A (BCN-335) and C (BCN-336). All dogs were treated again using a meglumine antimoniate liposomal formulation at a dose equivalent to 9.8 mgSb/kg/24 h for two 10-day periods, separated by an interval of 10 days [18]. Positive cultures were obtained again from dogs A (BCN-329), C (BCN-323) and F (BCN-331) at a range of times after treatment. (Figure 1)

Parasite isolation and in vitro maintenance was done through passages in NNN medium. Promastigotes from NNN were cultured in Schneider's insect medium at 26°C with 20% heat inactivated foetal calf serum (HIFCS). Their growth rate was then calculated, to establish the optimal conditions for in vitro susceptibility tests [19].

The pentavalent antimony used in in vitro assays was a solution of SbV in 8% hydrochloric acid at a concentration of 1 mg/mL (Varian Associates, Inc. Palo Alto, CA). Further working dilutions were performed in culture media. Previous assays demonstrated that the distinct working dilutions of HCl have no effect on the growing capacity of cultures [19].

Susceptibility test

The in vitro susceptibility tests to SbV were performed on intracellular amastigotes, cultured in the murine monocyte-macrophage cell line RAW 264.7 (American Type Culture Collection) in RPMI-1640 medium (Bio-Whittaker 12-1115; Boehringer-Ingelheim, Verriers, Belgium) with 10% of HIFCS in a 8 LabTeck Chamber Slide System (Nalge Nunc, Hamburg, Germany) as described previously [19]. Cells exposed to serial dilutions of the drug were cultured for 2 days at 37°C in a 5% CO2 atmosphere. Drug activity was evaluated by calculating the percentage of infected cells. Counting was performed at three places in the well and each assay was performed twice.

The concentration of SbV that produced a 50% reduction in infected cells (IC50) was determined from least-squares linear regression of growth rate or percentage vs. log antimony concentration.

Student's unpaired test was used to determine the statistical significance of the values obtained.

Authors contributions

Author JC carried out the studies on susceptibility, performed the statistical analysis and together with MP conceived the study and its design.

Both authors read and approved the final manuscript.

Acknowledgements

This research was supported by the Ministerio de Sanidad y Consumo of Spain, Projects FIS95-1342 and FIS97-2004 and by the Comissionat per Universitats i Recerca, Generalitat de Catalunya, Exp. 1997 SGR00341. We acknowledge the collaboration of Drs. M. Gállego, C. Riera and J.E. Valladares in animal infections and strains isolation and maintenance. The authors thank Robin Rycroft for correcting the English manuscript and Merial Labs S.A. for providing Glucantime.

References

  1. Desjeux P: Leishmaniasis: Public health aspects and control.

    Clin Dermatol 1996, 14:417-423. PubMed Abstract | Publisher Full Text OpenURL

  2. Desjeux P: The increase in risk factors for leishmaniasis worldwide.

    Trans R Soc Trop Med Hyg 2001, 95:239-243. PubMed Abstract OpenURL

  3. Gramiccia M, Gradoni L, Orsini S: Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.

    Ann Trop Med Parasitol 1992, 86:613-620. PubMed Abstract OpenURL

  4. Oliva G, Gradoni L, Ciaramella P, De Luna R, Cortese L, Orsini S, Davidson RN, Persechino A: Activity of liposomal amphotericin B (Ambisome) in dogs naturally infected with Leishmania infantum.

    J Antimicrob Chemother 1995, 36:1013-1019. PubMed Abstract OpenURL

  5. Vexenat JA, Olliaro PL, Fonseca de Castro JA, Cavalcante R, Furtado Campos JH, Tavares JP, Miles MA: Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromomycin).

    Am J Trop Med Hyg 1998, 58:448-453. PubMed Abstract | Publisher Full Text OpenURL

  6. Koutinas AF, Saridomichelakis MN, Mylonakis ME, Leontides L, Polizopoulou Z, Billinis C, Argyriadis D, Diakou N, Papadopoulos O: A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis.

    Vet Parasitol 2001, 98:247-261. PubMed Abstract | Publisher Full Text OpenURL

  7. Grogl M, Thomason TN, Franke ED: Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease.

    Am J Trop Med Hyg 1992, 47:117-126. PubMed Abstract OpenURL

  8. Jackson JE, Tally JD, Ellis WY, Mebrahtu YB, Lawyer PG, Were JB, Reed SG, Panisko DM, Limmer BL: Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy.

    Am J Trop Med Hyg 1990, 43:464-480. PubMed Abstract OpenURL

  9. Faraut-Gambarelli F, Piarroux R, Deniau M, Giusiano B, Marty P, Michel G, Faugère B, Dumon H: In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.

    Antimicrob Agents Chemother 1997, 41:827-830. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  10. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D: Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

    J Infect Dis 1999, 180:564-567. PubMed Abstract | Publisher Full Text OpenURL

  11. Carrió J, Riera C, Gállego M, Portús M: In vitro activity of pentavalent antimony derivatives on promastigotes and intracellular amastigotes of Leishmania infantum strains from humans and dogs in Spain.

    Acta Trop 2001, 79:179-183. PubMed Abstract | Publisher Full Text OpenURL

  12. Grogl M, Oduola AMJ, Cordero LDC, Kyle DE: Leishmania spp.: Development of Pentostam-resistant clones in vitro by discontinuous drug exposure.

    Exp Parasitol 1989, 69:78-90. PubMed Abstract OpenURL

  13. Carrió J, Riera C, Gállego M, Ribera E, Portús M: In vitro susceptibility of Leishmania infantum to meglumine antimoniate in isolates from repeated leishmaniasis episodes in HIV-coinfected patients.

    J Antimicrob Chemother 2001, 47:120-121. PubMed Abstract | Publisher Full Text OpenURL

  14. Garin YJF, Sulahian A, Pratlong F, Méneceur P, Gangneux JP, Prina E, Dedet JP, Derouin F: Virulence of Leishmania infantum is expressed as a clonal and dominant phenotype in experimental infections.

    Infect Immun 2001, 69:7365-7373. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  15. Fisa R, Gállego M, Castillejo S, Aisa MJ, Serra T, Riera C, Carrió J, Gállego J, Portús M: Epidemiology of canine leishmaniosis in Catalonia (Spain) the example of the Priorat focus.

    Vet Parasitol 1999, 83:87-97. PubMed Abstract | Publisher Full Text OpenURL

  16. Riera C, Valladares JE, Gállego M, Aisa MJ, Castillejo S, Fisa R, Ribas N, Carrió J, Alberola J, Arboix M: Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate.

    Vet Parasitol 1999, 84:33-47. PubMed Abstract | Publisher Full Text OpenURL

  17. Valladares JE, Riera C, Alberola J, Gállego M, Portús M, Cristòfol C, Franquelo C, Arboix M: Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.

    Vet Parasitol 1998, 75:33-40. PubMed Abstract | Publisher Full Text OpenURL

  18. Valladares JE, Riera C, González-Ensenyat P, Díez-Cascón A, Ramos G, Solano-Gallego L, Gállego M, Portús M, Arboix M, Alberola J: Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation.

    Vet Parasitol 2001, 97:15-21. PubMed Abstract | Publisher Full Text OpenURL

  19. Carrió J, de Colmenares M, Riera C, Gállego M, Arboix M, Portús M: Leishmania infantum: Stage-specific activity of pentavalent antimony related with the assay conditions.

    Exp Parasitol 2000, 95:209-214. PubMed Abstract | Publisher Full Text OpenURL